Literature DB >> 22416572

Targeted delivery of methotrexate to tumor cells using biotin functionalized methotrexate-human serum albumin conjugated nanoparticles.

Azade Taheri1, Rassoul Dinarvand, Fatemeh Atyabi, Faranak Nouri, Fatemeh Ahadi, Mohammad Hossein Ghahremani, Seyed Nasser Ostad, Atefeh Taheri Borougeni, Pooria Mansoori.   

Abstract

Systemic toxicity following cancer chemotherapy is an important concern. Targeted drug delivery systems could reduce the toxicity of anticancer drugs. Vitamins have been considered as targeting moieties in novel cancer treatment strategies. In this study, biotin was attached to nanoparticles of conjugated methotrexate-human serum albumin. Biotin functionalized methotrexate-human serum albumin with three different amounts of biotin attached to the nanoparticles were prepared. It was shown that the cytotoxicity of biotin functionalized nanoparticles on T47D and HeLa tumor cells was significantly higher than that of free methotrexate and non-functionalized nanoparticles. The cytotoxicity of biotin functionalized nanoparticles further increased when the number of biotin molecules attached on the surface of nanoparticles increased. The uptake of FITC labeled biotin functionalized nanoparticles by T47D and HeLa cells measured by flow cytometry, was also higher than that of non-functionalized nanoparticles. It can be concluded that the biotin functionalized methotrexate-human serum albumin conjugated nanoparticles could be used as a potent drug for specific delivery of methotrexate to tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22416572     DOI: 10.1166/jbn.2011.1340

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  3 in total

Review 1.  Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.

Authors:  Sean M Geary; Aliasger K Salem
Journal:  Crit Rev Oncog       Date:  2014

2.  Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy.

Authors:  Azade Taheri; Rassoul Dinarvand; Faranak Salman Nouri; Mohammad Reza Khorramizadeh; Atefeh Taheri Borougeni; Pooria Mansoori; Fatemeh Atyabi
Journal:  Int J Nanomedicine       Date:  2011-09-08

Review 3.  Recent advances in "smart" delivery systems for extended drug release in cancer therapy.

Authors:  Regina-Veronicka Kalaydina; Komal Bajwa; Bessi Qorri; Alexandria Decarlo; Myron R Szewczuk
Journal:  Int J Nanomedicine       Date:  2018-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.